Loading...
LYRA logo

Lyra Therapeutics, Inc.OTCPK:LYRA Stock Report

Market Cap US$1.2m
Share Price
US$0.74
US$16
95.4% undervalued intrinsic discount
1Y-85.0%
7D-1.3%
1D
Portfolio Value
​
View

Lyra Therapeutics, Inc.

OTCPK:LYRA Stock Report

Market Cap: US$1.2m

Lyra Therapeutics (LYRA) Stock Overview

A clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. More details

LYRA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Risk Analysis

Earnings have declined by 12.2% per year over past 5 years

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

+ 3 more risks

LYRA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Lyra Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lyra Therapeutics
Historical stock prices
Current Share PriceUS$0.74
52 Week HighUS$37.50
52 Week LowUS$0.31
Beta0.69
1 Month Change4.96%
3 Month Change-26.73%
1 Year Change-84.99%
3 Year Change-99.47%
5 Year Change-99.81%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Jun 16

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Summary Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, strong supporting data, and a good explanation for the ENLIGHTEN-1 failure, I believe the market is underestimating the potential for NDA submission without the need of another phase 3. Assuming positive FDA feedback, I expect considerable upside, allowing LYRA to raise much needed cash from a strong position. However, the FDA asking for another phase 3 trial would delay commercialization by several years. Without a partnership or other transaction, this would mean considerable dilution. Read the full article on Seeking Alpha
Analysis Article • Jan 25

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Sep 10

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 05

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics (NASDAQ:LYRA) has appointed Dr. Richard Nieman as Chief Medical Officer, effective July 11, 2022.  The industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the company's late-stage product candidates advance in the clinic. Dr. Nieman assumes the role of Chief Medical Officer, previously held by Dr. Robert Kern, who will continue to work closely with the company in the role of Chief Clinical Advisor. The firm has approved the issuance of an equity-based award pursuant to its 2022 Inducement Award Plan to Dr. Nieman upon the commencement of his employment.  The inducement grant consists of a non-qualified stock option to purchase an aggregate of 230,000 shares of the company's common stock.
Seeking Alpha • May 18

Lyra Therapeutics: Progress In The Clinic

Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile. The company is well funded. In this risk-off environment, there may be an even better entry point for investors.
Seeking Alpha • Apr 21

A First Look At Lyra Therapeutics

Today, we put Lyra Therapeutics in the spotlight for the first time. This small biopharma concern has disappointed investors since coming public in mid-2020. The drop in the shares has triggered some huge insider buying by insiders and beneficial owners of the stock via a capital raise in April. Time to buy this equity? A full investment analysis follows in the paragraphs below.
Analysis Article • Mar 30

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 14

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

LYRAUS PharmaceuticalsUS Market
7D-1.3%0.1%1.5%
1Y-85.0%41.1%28.6%

Return vs Industry: LYRA underperformed the US Pharmaceuticals industry which returned 44.6% over the past year.

Return vs Market: LYRA underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is LYRA's price volatile compared to industry and market?
LYRA volatility
LYRA Average Weekly Movement24.3%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: LYRA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LYRA's weekly volatility has decreased from 48% to 24% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200527n/alyratherapeutics.com

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.

Lyra Therapeutics, Inc. Fundamentals Summary

How do Lyra Therapeutics's earnings and revenue compare to its market cap?
LYRA fundamental statistics
Market capUS$1.24m
Earnings (TTM)-US$28.92m
Revenue (TTM)US$398.00k
3.3x
P/S Ratio
0.0x
P/E Ratio

Is LYRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYRA income statement (TTM)
RevenueUS$398.00k
Cost of RevenueUS$1.01m
Gross Profit-US$608.00k
Other ExpensesUS$28.31m
Earnings-US$28.92m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-16.29
Gross Margin-152.76%
Net Profit Margin-7,266.08%
Debt/Equity Ratio0%

How did LYRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 15:04
End of Day Share Price 2026/05/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lyra Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Matthew CaufieldH.C. Wainwright & Co.
Christopher HowertonJefferies LLC